test

A Phase II Trial of Carboplatin/Paclitaxel with and without Trastuzumab in HER2/neu+ Patients with Advanced orRecurrent Uterine Serous Papillary Cancer

Conditions

Corpus Uteri

What is the purpose of this trial?

To estimate whether the addition of trastuzumab to paclitaxel and carboplatin chemotherapy improves progression free survival (PFS) when compared to paclitaxel and carboplatin alone in USPC patients overexpressing HER2/neu at 3+ level by IHC or positive by FISH.


Participation Guidelines

Age:
Gender:

Click here for detailed information about who can participate in this trial.


Sponsor:
Yale Cancer Center
Dates:
05/06/2013
Last Updated:
Study HIC#:
1012007786